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ABSTRACT
Purpose: We determined the frequency of recurrent hotspot mutations in 46 
cancer-related genes across tumor histologies in patients with advanced cancer. 
Methods: We reviewed data from 500 consecutive patients who underwent 
genomic profiling on an IRB-approved prospective clinical protocol in the Phase I 
program at the MD Anderson Cancer Center. Archival tumor DNA was tested for 740 
hotspot mutations in 46 genes (Ampli-Seq Cancer Panel; Life Technologies, CA).
Results: Of the 500 patients, 362 had at least one reported mutation/variant. 
The most common likely somatic mutations were within TP53 (36%), KRAS (11%), 
and PIK3CA (9%) genes. Sarcoma (20%) and kidney (30%) had the lowest 
proportion of likely somatic mutations detected, while pancreas (100%), colorectal 
(89%), melanoma (86%), and endometrial (75%) had the highest. There was high 
concordance in 62 patients with paired primary tumors and metastases analyzed. 
151 (30%) patients had alterations in potentially actionable genes. 37 tumor types 
were enrolled; both rare actionable mutations in common tumor types and actionable 
mutations in rare tumor types were identified.
Conclusion: Multiplex testing in the CLIA environment facilitates genomic 
characterization across multiple tumor lineages and identification of novel 
opportunities for genotype-driven trials.
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INTRODUCTION
The use of molecular profiling in cancer research and 
clinical care has begun to rapidly evolve due to changes in 
available technology, applicability to patient samples, and 
decreases in the cost of sequencing technologies. Given 
the resources now available, there has been an increasing 
interest in creating personalized medicine platforms to 
allow selective assessment of a given patient’s tumor in 
real time, with the ability to utilize that information for 
patient care decisions. International profiling efforts such 
as The Cancer Genome Atlas Project (TCGA) [1] and the 
International Cancer Genome Consortium have begun to 
establish the baseline mutational profile of various cancers 
[2], but the application of this molecular knowledge in the 
care of individual patients has yet to be fully realized. 
Furthermore the population of patients and tumors 
analyzed in these international efforts frequently does not 
reflect those likely to enter clinical trials. At the University 
of Texas MD Anderson (MD Anderson), the Institute for 
Personalized Cancer Therapy (IPCT) has established 
protocols for molecular profiling of patient tumors with 
the goal of establishing personalized medicine platforms 
for individualized cancer care. Other groups have 
undertaken pilot studies of this type [3], although thus far 
the overall number of cancer patients enrolled onto these 
types of protocols has been small, predominantly due to 
the need for significant institutional support for large-scale 
endeavors of this type and the lack of adequate numbers 
of clinical trials with targeted agents. Thus the spectrum 
of aberrations seen in patients likely to enter clinical trials 
both within and across diseases remains only partially 
realized.
The utility of pairing the molecular profiling 
of tumors and the application of targeted therapies is 
exemplified by the success of this approach in Her2-
positive breast cancer [4] and BRAF V600E mutated 
melanoma [5] amongst others. Although improvements 
in outcomes have been demonstrated with the selective 
application of therapies to an identified cohort of likely 
benefit, even within a given cancer type, there is a 
distribution of activating mutations amongst patients that 
creates heterogeneity of the patient population and impacts 
eligibility for treatment with targeted agents. The use of a 
multi-gene screening panel may potentially allow a more 
personalized approach to cancer therapy by identifying 
less common but potentially actionable mutations across 
diseases as well as rare mutations within diseases. 
However, the relationship between molecular targeting, 
the intrinsic gene expression pattern in the lineage, the 
presence of co-mutations and the tumor microenvironment 
is complicated and actionability of mutations may vary 
from one tissue and one patient to another.
We examined the first 500 patients with advanced 
cancer and sequenced on the IPCT molecular profiling 
study in the Department of Investigational Cancer 
Therapeutics (the Phase I Program) at MD Anderson, a 
population of patients representing multiple disease sites, 
in order to compare the utility and findings of a molecular 
profiling platform in a heterogeneous patient population 
with advanced cancer likely to enter clinical trials. 
RESULTS
The first 500 patients sequenced on this Institutional 
Review Board (IRB)-approved protocol in the Department 
of Investigational Cancer Therapeutics were analyzed. In 
the same time periods 117 patients consented to the study 
but did not undergo sequencing due to lack of available 
archival tissue or inadequate quantity DNA. Almost all 
patients had archival tissue used for analysis (surgical 
samples or core biopsies in FFPE), median time from the 
original sample acquisition was 582 days. Nearly two 
thirds had primary tumors analyzed. The median time 
from study consent to return of genomic sequencing data 
was 17 days.
Of 500 patients who underwent genomic sequencing 
362 patients (72%) had at least one alteration detected 
on this 46 gene panel (Figure 1 and Table 1). Of the 
mutations detected, 298 were from single patient samples, 
while 64 patients had paired primary and metastatic 
samples available for analysis. Amongst the mutations 
found, 22 mutations in 12 genes were classified as likely 
germline variants as determined by definitions described 
in Methods. The most common germline variants found 
were in KIT (17%), MET (6%), ATM (5%), KDR (5%), 
and TP53 (2%) with variable representation in other 
genes. The remaining mutations were designated as 
“likely somatic” and will be referred to as somatic in 
the subsequent text. Based on this definition, somatic 
mutations were detected in 286 out of a total of 500 
patients (57%) representing 240 single patient samples 
and 46 patients with paired primary and metastasis. A gene 
was considered actionable if its product can be targeted 
with an approved or investigational therapy either directly 
or indirectly targeted (by targeting a downstream pathway 
[9]). The definition of actionable was not tissue-specific 
and may not reflect therapeutic efficacy or availability 
across cancer types. We next identified 26 genes with 
actionable targets, which we designated as potentially 
actionable and found 89 actionable mutations present 
in 151 patients (30%) representing 127 single patient 
samples and 24 primary/metastasis pairs.
Our initial approach was to examine mutations 
across all tumor types represented to establish an overview 
of the mutational landscape across diseases (Figure 2). 
Subsequently, we elected to look in more detail at mutation 
frequencies in tumors with greater patient representation 
(n ≥ 10 samples). The distribution of these tumor types can 
be seen in Figure 3. The most common tumors submitted 
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Table 1: CMS46 hotspot mutation/variants in tumor types (n > 10 pts)
Tumor Type Mutation (%) Somatic (%) Actionable (%) Actionable w/o KRAS (%) Total Pt #
Ovarian 81 48 16 10 58
Sarcoma 47 20 6 6 49
Colorectal 91 89 66 27 44
Lung 83 74 54 46 35
Head & Neck 72 49 15 15 39
Breast 80 70 43 43 30
Esophageal 79 57 18 18 28
Kidney 57 30 4 4 23
Gastric 76 67 19 19 21
Melanoma 87 80 80 80 15
Prostate 57 36 7 7 14
Liver 57 43 14 14 14
Pancreatic 100 100 85 23 13
Endometrial 89 78 39 33 18
Neuroendocrine 72 26 9 9 11
Thyroid 73 64 64 55 11
Figure 1: Flowchart of first 500 patients sequenced on a genomic profiling protocol in the Department of Investigational 
Cancer Therapeutics. Of the first 500 patients enrolled on the IPCT protocol, 362 (72%) were found to have variants on the 46-gene 
panel screening. Of these 74 patients (15%) had likely germline variants, which were excluded for subsequent analysis. The following 286 
patients (57%) had likely somatic mutations found in 39 genes. Of these, 151 patients (30%) had potentially actionable mutations in 26 
genes.
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for analyses were ovarian (n = 52), sarcoma (n = 49), 
and colorectal (n = 44). Proportionally pancreatic tumors 
had the largest number of mutations detected (100% 
overall, 100% somatic, 85% potentially actionable, noting 
that KRAS was designated potentially actionable in this 
analysis). This was followed by melanoma (93% overall, 
86% somatic, 86% actionable) and colorectal cancer (91% 
overall, 89% somatic, 66% actionable). On the other 
end of the spectrum, sarcoma had the lowest proportion 
of mutations detected on this panel (47% overall, 20% 
somatic, 8% actionable) (Figure 4 and Table 1). Frequency 
of KRAS mutations and actionable mutations excluding 
KRAS by tumor type is demonstrated in this figure. 
Looking across disease types at the overall incidence of 
somatic mutations (Figure 5) demonstrates that TP53 was 
the most commonly mutated gene followed by KRAS, 
and PIK3CA. However, when looking exclusively at 
the proportion of mutations in potentially actionable 
genes, KRAS, PIK3CA, BRAF, and EGFR were the most 
commonly detected actionable mutations.
Breaking down the data according to cancer type, it 
becomes clear that melanoma has the highest proportion 
of potentially actionable mutations (mostly BRAF), 
followed by pancreatic cancer (KRAS) and colorectal 
cancer (KRAS and PIK3CA) as seen in Figure 5. It is 
notable that although our study population is limited to 
patients who had multiplex testing after being referred to 
the Department of Investigational Cancer Therapeutics, 
it is possible that selected patients already had single 
gene testing and had identified mutations (e.g. BRAF 
mutations), thus enriching for populations with actionable 
targets in certain diseases. 
Next, we examined the proportion of potentially 
actionable mutations within the various cancer types 
present in our patient population (Figure 6). Mutations in 
KRAS were most common in pancreatic cancer followed 
by colorectal cancer. BRAF and NRAS mutations were 
most common in melanoma. PIK3CA mutations were most 
common in breast cancer, and EGFR mutations were most 
common in lung cancer. 
We then examined 64 paired primary and metastatic 
samples from this cohort; 46 pairs (72%) had somatic 
Figure 2: Number of patients with likely somatic mutations seen by tumor type. The most common tumor profiled was 
ovarian, followed by sarcoma, colorectal and lung cancer. However, the distribution of tumors with mutations detected varied by tumor 
type. For example, despite a large number of sarcoma patients within this population (n = 49), the proportion of likely somatic mutations 
detected in sarcoma patients was relatively low (20%).
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Figure 3: Relative distribution of samples across tissue types (n > 10). Only tumor types with more than 10 patients were 
analyzed in the subsequent analysis, and the relative proportion of those tumor types can be seen in this pie chart. The absolute numbers 
are as follows: ovarian (n = 58), sarcoma (n = 49), colorectal (n = 44), lung (n = 35), head & neck (n = 35), breast (n = 30), esophageal 
(n = 28), kidney (n = 23), gastric (n = 21), melanoma (n = 15), prostate (n = 14), liver (n = 14), pancreatic (n = 13), endometrial (n = 18), 
neuroendocrine (n = 11), and thyroid (n = 11) and other (n = 77).
Figure 4: Percentage of patients with type of variants seen by tumor type. The data was reviewed according to tumor type a)nd 
demonstrated great variation in the proportion of KRAS, potentially actionable somatic mutations excluding KRAS, non-actionable somatic, 
likely germline variants, and absence of mutations found using our 46 gene panel. While sarcoma has the fewest number of mutations/
variants detected, pancreatic tumors had no germline variants found and melanoma had the largest proportion of potentially actionable 
mutations detected. Many of these findings may represent the inherent selection bias of mutations represented on the gene panel, which has 
been focused on identifying known actionable mutations with potential therapeutic targets.
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mutations detected on this platform; 24 pairs (52%) had 
actionable mutations. Analysis was undertaken to examine 
the concordance of mutations detected between paired 
primary and metastatic lesions (Figure 7). We found 
highly similar mutations in paired samples from primary 
and metastatic tumors, both when looking at all somatic 
mutations as well examining the subgroup of actionable 
mutations exclusively. There was one colorectal patient 
who had a SMAD4 mutation detected in the primary tumor 
that was not detected in the paired metastasis and one 
patient with fallopian tube tumor who had a RET mutation 
in the primary (not detected in the metastasis) and a TP53 
mutation in the metastasis (not detected in the primary). 
When looking solely at potentially actionable mutations, 
there was concordance between all but one paired primary 
and metastatic samples (Figure 7). The high degree of 
concordance may reflect the depth of sequencing being 
able to detect mutations present in subclones or may 
alternatively reflect the limited heterogeneity in the 
hotspot mutations analyzed given the limitations of a 46 
gene panel. 
Finally, we examined the co-occurrence and 
exclusivity of various mutations (Figure 8). The most 
notable findings were the mutual exclusivity between 
somatic mutations in TP53 and PIK3CA (p = 0.00004), 
FBXW7 (p = 0.008), BRAF and KRAS (p = 0.01), and the 
co-occurrence of somatic mutations in KRAS and SMAD4 
(p = 0.008), KRAS and APC (p = 0.002) and HRAS 
and PIK3CA (p = 0.03) (Figure 8A). Looking only at 
potentially actionable mutations, there was significant co-
occurrence between KRAS and PIK3CA (p = 0.006), KRAS 
and BRAF (p = 0.002), and BRAF and PIK3CA (p = 0.01) 
(Figure 8B). It is unclear whether these events are solely 
driven by “mutual exclusivity” of the pathways involved 
or the potential that particular mutation events dominate 
specific lineages (i.e. PIK3CA mutations in luminal breast 
cancer and TP53 in basal breast cancer), but warrants 
further investigation.
DISCUSSION
The current study has examined the landscape of 
mutations found in a heterogeneous population of patients 
with advanced cancer enrolled on a genomic profiling 
protocol at a dedicated cancer center. We analyzed the 
first 500 patients tested on a hotspot mutation panel 
enrolled through the Department of Investigational Cancer 
Therapeutics at MD Anderson, filtering out probable 
germline variants and looking more closely at somatic and 
actionable mutations found through hotspot profiling using 
the 46 gene panel. We were able to detect likely somatic 
mutations in over half of our patients (57%) and mutations 
in actionable genes in 30% of the overall population 
(Figure 1).
Figure 5: Number of mutations by gene. A. Likely somatic mutations are displayed according to the gene involved, with mutations 
in TP53 being most common (n = 179), followed by KRAS (n = 56) and PIK3CA (n = 44). The median number of somatic mutations per 
gene was 1. B. A subset of these genes, identified as potentially actionable mutations are listed according to the gene involved, with KRAS 
being the most common actionable mutation (n = 56), followed by PIK3CA (n = 44), and BRAF (n = 21). 
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As noted, a gene was considered actionable if it 
could be directly or indirectly targeted with an approved 
or investigational therapy and there is some evidence of 
preclinical/clinical effectiveness in tumors harboring 
genetic alterations in the gene [9]. This definition is not 
tissue-specific and may not reflect therapeutic efficacy or 
clinical relevance across all cancer types. Furthermore, it 
does not reflect availability of trials for a specific patient 
which may be limited due to tumor site, slots on the trial 
or disqualifying criteria for trials such as performance 
status, prior therapy, brain metastasis or prior malignancy. 
It has been well-established that within the same gene, 
the type and site of mutation identified (with resultant 
differences in protein expression and function) may 
manifest with variable functional and biologic effects. 
Therefore, the definition of a gene as “actionable” is an 
oversimplification; not all mutations in that gene affect 
function and are “actionable”. 
In our study TP53 is not included in our 
classification of potentially actionable mutations, 
although there are studies utilizing TP53 as a biomarker 
of therapeutic response, approaches to inhibit dominant-
negative functions of mutant p53, and therapies to rescue 
p53 loss of function. In breast cancer, TP53 mutations 
have been used as a marker of responsiveness to dose-
dense epirubicin-cyclophosphamide [10] while in non-
small cell lung carcinoma (NSCLC) it has been used as 
a marker of responsiveness to carboplatin/gemcitabine 
[11]. While the role of TP53 mutations in chemo-naïve 
colorectal cancer patients is unclear [12-14], mutant TP53 
is a predictor of better clinical outcomes in patients with 
chemotherapy-refractory metastatic colorectal cancer 
treated with cetuximab [15]. This variability in mutational 
profiling findings amongst different diseases and in 
distinct clinical scenarios demonstrates the difficulty in 
classification schemata of this type. Additionally, there are 
current trials targeting either wild type or mutant TP53 
suggesting use as positive and negative selection strategy 
(i.e. inclusion or exclusion criteria respectively). However, 
due to the limited number of hotspots in TP53 being 
targeted, we decided to consider TP53 as not actionable at 
this time. In this analysis IDH1/2 was also not considered 
actionable due to lack of trials addressing these alterations 
in solid tumors at the time of this study. 
Similarly, in our analysis KRAS was classified as 
potentially actionable, despite its use in many studies as 
a negative predictor of EGFR-targeted therapy inhibitors 
[16] and being used as an exclusion criteria in a number 
Figure 6: Frequency of potentially actionable mutations by cancer type. This figure focuses exclusively on potentially 
actionable mutations, stratifying the gene mutations according to tumor type to demonstrate the relative abundance of these mutations 
across the various cancers included in this study. KRAS mutations are most commonly seen in pancreatic and colorectal tumor specimens, 
BRAF mutations are most commonly found in melanoma samples, and PIK3CA mutations are most commonly detected in breast cancer 
samples as you would expect. However, there are a smaller proportion of actionable mutations found in tumors less commonly associated 
with these mutations, such as NRAS mutations in breast cancer and PIK3CA mutations in lung cancer.
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of other trials. Our choice of inclusion of KRAS as an 
actionable target relates to the fact that there are early 
ongoing trials focused on downstream targeting of the 
MAPK pathway in KRAS mutant patients [17, 18], 
making it a potentially actionable target in some tumor 
types. Therefore, despite our current classification system, 
KRAS may not be actionable target, at least not simply 
targetable with single agent targeted therapy, in many 
diseases, including those in which the mutations occur in 
high proportion (e.g. pancreatic cancer) [19]. Therefore we 
displayed % of patients with mutations in actionable gene 
without KRAS in separately in Figure 4.
More work on these topics and curation of our 
findings is ongoing as clinical data accumulates. These 
examples demonstrate the complexity of profiling 
studies, particularly when examining mutational 
profiling across multiple cancers. Moving forward, cross-
tumor comparison of mutational findings must include 
supporting and conflicting data to guide best-practice 
treatment decisions for patients. Other current limitations 
to studies of this type include the availability of slots 
on appropriate clinical trials even when data supporting 
matching of patients to trials of targeted therapies are 
available. This approach must account for the availability 
or lack of availability of appropriate trials within the 
institution. Finally, given the advanced nature of the 
disease in our patient population, there may be difficulties 
with patient eligibility for trials, even when trials are open 
and slots available. Therefore, the success of a program of 
this type will require continual data curation and iterative 
analysis, integration with disease-specific treatment teams 
and clinical trial groups, and an institutional commitment 
to multi-specialty management and application of a 
personalized medicine program.
Clearly the distribution of patients presented here 
is not representative of cancer patients at large. To avoid 
a referral bias, we focused this study to not all patients 
referred to the Department of Investigational Cancer 
Therapeutics (presuming patients with genomic alterations 
would be more likely referred) but rather those enrolled 
on the genomic profiling protocol in the Department It is 
notable that although our study population is limited to 
patients who had multiplex testing after being referred to 
the Department of Investigational Cancer Therapeutics, 
it is possible that selected patients already had single 
gene testing and had identified mutations (e.g. BRAF 
mutations), thus enriching for populations with actionable 
targets in certain diseases.There was certainly a referral 
bias impacting enrollment on this protocol and our data 
is not representative of the entire spectrum of patients 
seen in our Phase I program. The sample was enriched 
in patients with common mutations (e.g. BRAF-mutant 
melanoma), making the percentages of these patients 
higher than that which would be seen in the normal disease 
population. Not surprisingly, there were a high proportion 
of detected mutations in cancer types with known genetic 
alterations, such as colorectal cancer, pancreatic cancer, 
and melanoma given the selection of known actionable 
genes for use in the 46 gene panel. Additionally, the high 
proportion of mutations detected (greater than that which 
occurs in the baseline cancer population) may be related 
to pre-referral bias of patients selected for enrollment on 
Figure 7: Concordance of mutations between matched primary and metastatic tumors. 64 paired primary and metastatic 
pairs were examined; 46 pairs had somatic mutations, 24 pairs had actionable mutations. There is high concordance between primary 
and metastatic tumors, looking at both somatic and potentially actionable mutations. There was one colorectal patient who had a SMAD4 
mutation detected in the primary tumor that was not detected in the paired metastasis and one patient with fallopian tube tumor who had 
a RET mutation in the primary not detected in the metastasis and a TP53 mutation in the metastasis that was not detected in the primary. 
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this protocol. Diseases with well-characterized mutations 
were well-captured on this study (Figures 5 and 6, Table 
1), demonstrating the utility of this streamlined approach 
in these particular patient populations. Less well-
characterized cancers, such as sarcomas, were also well-
represented in our patient population (n = 49) although the 
proportion of detected mutations with this panel were low 
(47% overall, 20% somatic, 6% actionable). This suggests 
that more extensive genomic profiling platforms, and 
in particular an ability to detect fusion genes, may have 
greater utility in patients with advanced sarcoma. Notably 
expanded mutation panels covering a larger number of 
actionable genes, the entire sequence of genes (especially 
tumor suppressor genes), as well as assays that give copy 
number variation is likely to lead to higher percentage of 
patients with actionable genomic alterations in each tumor 
type.
While successful discovery of known actionable 
targets for therapeutic selection is a high priority for 
studies of this type, we were also interested to examine the 
less common mutations identified through this molecular 
screening platform. While mutations in KRAS, BRAF, 
PIK3CA, and EGFR were found in cancer types expected, 
there were also several instances of actionable mutations 
identified in diseases for which these mutations have not 
been well characterized. For example, HRAS mutations 
were identified in a subset of patients with head and 
neck cancers, suggesting that use of downstream ERK or 
MEK inhibitors may be of benefit. Molecular screening 
techniques of this type when integrated into clinical 
decision-making systems may offer the opportunity 
for cross-cancer enrollment onto clinical trials and 
identification of patients who may benefit from targeted 
second or third-line therapies when standard-of-care 
regimens have failed.
Given the presence of paired samples from primary 
and metastatic sites within the same patients enrolled on 
protocol, we were also able to examine the concordance 
of identified mutations between primary and metastatic 
sites. We found a high concordance of mutations between 
the primary and temporally distant recurrent/metastatic 
sites, particularly when looking at actionable mutations. 
This suggests that archival tissue as well as newly biopsied 
samples may be appropriate for profiling and therapeutic 
selection in the majority of cases, expanding the cohort 
of patients who may be eligible for this type of profiling 
Figure 8: Mutual exclusivity and co-occurrence of mutations. When examining the co-occurrence and exclusivity of various 
mutations the most notable findings were the mutual exclusivity between somatic mutations in TP53 and PIK3CA (p = 0.00004), FBXW7 
(p = 0.008), BRAF and KRAS (p = 0.01), and the co-occurrence of KRAS and SMAD4 (p = 0.008), KRAS and APC (p = 0.002) and HRAS 
and PIK3CA (p = 0.03) (Figure 8a). Looking only at potentially actionable mutations, there was significant co-occurrence between KRAS 
and PIK3CA (p = 0.006), KRAS and BRAF (p = 0.002), and BRAF and PIK3CA (p = 0.01) (Figure 8b).
Oncotarget20108www.impactjournals.com/oncotarget
approach. However several studies, including our own 
previous studies, have shown that there may be genomic 
evolution with progression and selection pressure with 
targeted therapy [20-22]. Thus, repeat biopsy and profiling 
may be a considered as clinically indicated particularly 
when larger panels of aberrations are considered. 
Finally, we examined the co-occurrence and mutual 
exclusivity of mutations, in order to address the concept 
of personalized profiling to inform decisions regarding 
the benefit (or potential lack of utility) of combinatorial 
therapies for specific patients with frequently occurring 
co-mutations. We found that within the samples with 
potentially actionable mutations, PIK3CA mutations and 
KRAS mutations were frequently co-occurring (p = 0.006), 
followed by KRAS and BRAF (p = 0.002), and PIK3CA 
and BRAF mutations (p = 0.01). The data presented here is 
generated from a small sample set and is not representative 
of each disease type, and thus should be considered 
hypothesis-generating only. However these results 
highlight a challenge to current genotype-selected single-
agent trial strategies, as patients may have more than one 
therapeutic target or may have an actionable alteration 
in the presence of a resistance marker. Future studies are 
planned to examine these trends within disease-specific 
cohorts, where assessment of therapeutic approaches may 
be more similar and predictable and combination therapies 
may be more easily applied and evaluated.
Overall, the utilization of molecular profiling 
as a real-time tool for practicing clinicians has arrived. 
The current dilemma is to facilitate the translation of 
molecular findings into clinical decision-making in a 
feasible timeframe with appropriate decision-support. 
While whole exome or genome profiling is appealing in its 
breadth, focused sequencing approaches such as hotspot 
mutational profiling, can be accomplished in a more-
realistic timeframe for use in day-to-day clinical care. 
We have demonstrated the feasibility of this approach in 
a heterogeneous patient population. Moving forward, we 
are integrating this data into treatment algorithms across 
cancer types with the goal of expanding the potential 
availability of targeted agents to the appropriately-
selected patients for whom some benefit of therapies may 
be expected. Much work still needs to be done to focus 
the target selection to capture the greatest proportion of 
mutations across various disease types, to capture genomic 
alterations in rare cancer types, and to optimize the 
process to be accessible to clinicians rendering care on a 
routine basis. This will include simplification of molecular 
data presentation, automatic curation of germline/
somatic/actionable mutation categories, determining 
the level of evidence for therapeutic implications of 
alterations in selected genes across multiple disease 
types, and building knowledge bases such as the websites 
“personalizedcancertherapy.org” (maintained by MD 
Anderson) and “mycancergenome” (initiated by Vanderbilt 
Cancer Center). Finally, it will require infrastructural 
foundations to build a pipeline of trials that leverage 
genomic testing and real-time processing and analytics to 
allow this type of data to be available, interpretable, and 
applicable to patients in a useful timeframe. 
MATERIALS AND METHODS
We reviewed data from the first 500 patients 
prospectively enrolled on the IRB-approved protocol 
in the in the Department of Investigational Cancer 
Therapeutics at MD Anderson. Hematoxylin and eosin 
stained tissue sections were reviewed, and tumor 
areas and tumor percentage cellularity was asssessed. 
Only specimens with > 20% tumor in the circled area 
were analyzed. Archival tumor DNA was tested in a 
Clinical Laboratory Improvement Amendments (CLIA) 
environment for 740 hotspot mutations in 46 genes (Suppl 
Table 1) (AmpliSeq Cancer Panel) using an Ion Torrent 
Personal Genome Machine Sequencer (Life Technologies, 
CA) [6]. This platform has already been extensively 
validated against orthogonal platforms [6-8]. Adequately 
covered amplicons were defined as those having total 
coverage depth of greater than or equal to 250 reads, or 
for which an orthogonal mutation analysis testing has 
been performed. For clinical purposes, we determined the 
effective lower limit of detection of this assay (analytical 
sensitivity) for single nucleotide variations to be in the 
range of 5% (one mutant allele in the background of 
nineteen wild type alleles) to 10% (one mutant allele in 
the background of nine wild type alleles) by taking into 
consideration the depth of coverage at a given base and the 
ability to confirm low level mutations using independent 
conventional platforms. Hot spot mutations as well as 
mutations detected in that region were reported. The data 
was analyzed using R Statistical Software (R Foundation 
for Statistical Computing, Vienna, Austria). 
Detected mutations were identified as either likely 
germline variants or likely somatic based upon pre-
established definitions (Suppl Table 2). Germline variants 
were defined by identifying and grouping variants based 
on relative prevalence within the MD Anderson patient 
population. The data was joined against dbSNP v.138 to 
pull in global minor allele frequency (GMAF) numbers 
where available. Mutations were labelled germline if 
GMAF was ≥ 0.001. Although TP53 R273H had a GMAF 
≥ 0.001, it was characterized as somatic due to additional 
supporting data. For outlier calls, variant frequency 
histograms for all patients at MD Anderson were examined 
to identify those demonstrating bimodal distribution, 
which would suggest hetero- and homozygous peaks 
consistent with germline variants. These histograms 
were created for all questionable outliers and germline 
calls in this group were made on a case-by-case basis. 
The designated somatic mutations were then filtered for 
mutations in 26 actionable genes (Suppl Table 3). Finally, 
these actionable mutations were analyzed for tissue-
Oncotarget20109www.impactjournals.com/oncotarget
specific relevance as well as for cross-tissue comparison. 
Tissue-types with ≥ 10 patients were included for further 
analysis.
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